ALK Inhibitors in Non–Small Cell Lung Cancer: How Many Are Needed and How Should They Be Sequenced?

  H&O  Which patients with non–small cell lung cancer (NSCLC) are candidates for treatment with crizotinib? AS  Crizotinib (Xalkori, Pfizer) is a multitargeted tyrosine kinase inhibitor […]